'Gut-on-chip' can predict immunotherapy outcomes for melanoma patients
A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...
Fierce Pharma16h
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
New drug delivery method promises long-lasting glaucoma relief
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...